Volume 131, Issue 2, Pages 470-477 (August 2006) Peginterferon and Ribavirin Treatment in African American and Caucasian American Patients With Hepatitis C Genotype 1  Hari S. Conjeevaram, Michael W. Fried, Lennox J. Jeffers, Norah A. Terrault, Thelma E. Wiley–Lucas, Nezam Afdhal, Robert S. Brown, Steven H. Belle, Jay H. Hoofnagle, David E. Kleiner, Charles D. Howell  Gastroenterology  Volume 131, Issue 2, Pages 470-477 (August 2006) DOI: 10.1053/j.gastro.2006.06.008 Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 1 Percentages of participants with undetectable serum HCV-RNA levels (<50 IU/mL) by racial group at selected time points. □, AA; ■, CA. Gastroenterology 2006 131, 470-477DOI: (10.1053/j.gastro.2006.06.008) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions

Figure 2 Relationship between baseline viral level (log10 IU/mL) and adjusted predicted percentage with SVR by race. The predicted probability of an SVR by baseline viral level is shown separately for AA and CA using the example of a man with an Ishak fibrosis score of 2 on pretreatment liver biopsy examination who took 80% of the maximum peginterferon dose during the first 24 weeks of treatment. Gastroenterology 2006 131, 470-477DOI: (10.1053/j.gastro.2006.06.008) Copyright © 2006 American Gastroenterological Association Institute Terms and Conditions